Furthermore, preclinical and clinical data from CD123-targeting antibody-based approaches, including flotetuzumab, support no evidence of myelosuppression [15,16,29], indicating that MDG006 is likely to be safe for use in pediatric AML. This evidence concerns the gene IL3RA and acute myeloid leukemia.